Roche Launches Game-Changing Lung Cancer Treatment in India

Swiss pharmaceutical giant Roche has unveiled Tecentriq SC, a groundbreaking subcutaneous immunotherapy for lung cancer in India. The new treatment significantly decreases the time patients need to spend in hospitals, with administration taking just seven minutes compared to the lengthy hours required for traditional IV infusions.

Sivabalan Sivanesan, Director of Medical and Regulatory Affairs at Roche India, highlighted the impact of this innovation, noting that with 80,000 lung cancer diagnoses in India annually, Tecentriq SC's unique formulation will expand patient reach and treatment accessibility.

Rajwinder Mehdwan, MD & CEO of Roche Pharma India, emphasized the company's dedication to enhancing cancer care access through innovative solutions that not only improve clinical outcomes but also streamline healthcare systems. The subcutaneous injection is expected to optimize healthcare resources and facilitate a shift toward more decentralized treatment settings.

(With inputs from agencies.)